• Annual Report 2021

العربية | ENGLISH

OPERATING PERFORMANCE

Statement of Cash Flows

For the year ended 31 December Notes 2021 SR 2020 SR
Operating activities
Total income for the year before Zakat and tax 55,886,161 64,123,853
Adjustments to reconcile total income for the year before Zakat and
tax to net cash used in operating activities:
Employees’ end of service benefits 19 1,341,020 1,123,174
Special commission income from bond and sukuk (10,134,671) (8,294,417)
Special commission expense from margin loan 432,140 9,969
Special commission income from time deposits (5,312,286) (10,729,027)
Amortization of discount and premium on held-to-maturity investments 18 (3,413,054) (2,952,591)
Depreciation of property and equipment 25 2,612,955 2,341,856
Gain on disposal of property and equipment (41,454)
Reversal of provision for Zakat (5,567,920)
Realized (gains)/losses on investments held at fair value through income statement 7(iii) (7,209,116) 885,373
Unrealized gains on investments held at fair value through income statement 7(iii) (4,912,672) (1,685,649)
Share of profit of equity-accounted investee 17 (18,657,921) (12,071,843)
Charge/(reversal) of doubtful debts 6 153,851 (647,860)
Operating income before changes in operating assets and liabilities 10,744,953 26,534,918
Changes in operating assets and liabilities:
Reinsurance premiums receivable, gross 51,371,704 (59,714,912)
Accrued reinsurance premiums (86,206,823) (127,192,211)
Retroceded share of unearned premiums 3,909,265 (21,024,988)
Unearned premiums 100,328,307 146,543,590
Retroceded share of outstanding claims 5,341,430 128,044,463
Retroceded share of claims incurred but not reported 7,763,206 (10,984,218)
Deferred acquisition costs (19,194,868) (43,124,178)
Deferred excess of loss premiums 734,131 (1,040,130)
Prepaid expenses, deposits and other assets 42,518,082 (44,458,986)
Accounts payable 12,067,123 (7,953,857)
Retrocession balances receivable 16,445,367 (13,600,729)
Retrocession balances payable (28,448,079) 15,138,226
Accrued retroceded premiums (4,320,405) 18,070,553
Outstanding claims 66,043,865 (20,282,406)
Claims incurred but not reported 76,654,955 (4,513,165)
Unearned commission income 1,344,444 7,409,113
Statutory deposit (8,100,000) 40,500,000
Accrued expenses and other liabilities 6,036,462 4,439,976
255,033,119 32,791,059
Zakat and tax paid 22 (14,913,138) (17,774,142)
Employees’ end of service benefits paid 19 (419,904) (14,670)
Net cash generated from operating activities 239,700,077 15,002,247
Investing activities
Addition in time deposits (308,318,750) (233,237,045)
Proceeds from maturity of time deposits 258,396,167 383,143,846
Accrued special commission income on time deposits 6,213,677 15,491,938
Accrued special commission income from bonds and sukuk 9,504,843 4,906,926
Purchase of property and equipment, net (6,143,496) (2,391,660)
Proceeds from sale of property and equipment 41,500
Additions in investments held at fair value through income statement 7(iii) (671,644,233) (500,020,456)
Proceeds from disposal of investments held at fair value through income statement 7(iii) 564,239,261 406,587,175
Additions in equity-accounted investment 17 (3,696,900)
Additions in held-to-maturity investments (110,586,537) (143,570,130)
Net cash used in investing activities (258,297,568) (72,786,306)
Financing activities
Proceeds from margin loans 10 33,680,203 23,116,816
Special commission expense paid against margin loans (432,140) (9,969)
Net cash generated from financing activities 33,248,063 23,106,847
Increase/(decrease) in cash and cash equivalents 14,650,572 (34,677,212)
Cash and cash equivalents at the beginning of the year 13,156,722 47,833,934
Cash and cash equivalents at the end of the year 5 27,807,294 13,156,722
Non-cash information
Remeasurement gain/(loss) on end-of-service benefit obligations 19 (694,084) (735,982)
Foreign currency impact on equity-accounted investment 17 (1,429,969) 2,926,703
Right-of-use asset 50,082 288,916
Lease liability 4,618 295,834

The accompanying notes 1 to 36 form an integral part of these financial statements.

Close